Your browser doesn't support javascript.
loading
International cancer seminars: a focus on kidney cancer.
Scelo, G; Hofmann, J N; Banks, R E; Bigot, P; Bhatt, R S; Cancel-Tassin, G; Chew, S K; Creighton, C J; Cussenot, O; Davis, I J; Escudier, B; Frayling, T M; Häggström, C; Hildebrandt, M A T; Holcatova, I; Johansson, M; Linehan, W M; McDermott, D F; Nathanson, K L; Ogawa, S; Perlman, E J; Purdue, M P; Stattin, P; Swanton, C; Vasudev, N S; Wu, X; Znaor, A; Brennan, P; Chanock, S J.
Affiliation
  • Scelo G; Section of Genetics, International Agency for Research on Cancer, Lyon, France.
  • Hofmann JN; Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA.
  • Banks RE; Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute for Cancer Studies and Pathology, St James' University Hospital, Leeds, UK.
  • Bigot P; Department of Urology, Centre Hospitalier Universitaire d'Angers, Angers, France.
  • Bhatt RS; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
  • Cancel-Tassin G; Groupe de Recherche GRC-UPMC n°5, Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France.
  • Chew SK; Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, University College London, London, UK.
  • Creighton CJ; Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston.
  • Cussenot O; Groupe de Recherche GRC-UPMC n°5, Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France.
  • Davis IJ; Department of Genetics, UNC School of Medicine, Chapel Hill, USA.
  • Escudier B; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
  • Frayling TM; University of Exeter Medical School, Exeter, UK.
  • Häggström C; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå Department of Biobank Research, Umeå University, Umeå, Sweden.
  • Hildebrandt MA; Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Holcatova I; Institute of Public Health and Preventive Medicine, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic.
  • Johansson M; Section of Genetics, International Agency for Research on Cancer, Lyon, France.
  • Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda.
  • McDermott DF; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
  • Nathanson KL; Department of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Ogawa S; Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
  • Perlman EJ; Department of Pathology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, USA.
  • Purdue MP; Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA.
  • Stattin P; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå
  • Swanton C; University College London Hospitals and Cancer Institute, London, UK.
  • Vasudev NS; Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute for Cancer Studies and Pathology, St James' University Hospital, Leeds, UK.
  • Wu X; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Znaor A; Section of Genetics, International Agency for Research on Cancer, Lyon, France.
  • Brennan P; Section of Genetics, International Agency for Research on Cancer, Lyon, France brennanp@iarc.fr.
  • Chanock SJ; Division of Cancer Epidemiology and Genetics, Department of Health and Human Service, National Cancer Institute, National Institutes of Health, Bethesda, USA brennanp@iarc.fr.
Ann Oncol ; 27(8): 1382-5, 2016 08.
Article in En | MEDLINE | ID: mdl-27130845
ABSTRACT
Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer. To summarize important achievements and identify prominent research questions that remain, a workshop was organized by IARC and the US NCI. A series of 'difficult questions' were formulated, which should be given future priority in the areas of population, genomic and clinical research.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genomics / Kidney Neoplasms Type of study: Etiology_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Francia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genomics / Kidney Neoplasms Type of study: Etiology_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Francia